 Heterocyclic Compounds, 2-Ring
"Heterocyclic Compounds, 2-Ring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of heterocyclic compounds that include a two-ring fused structure. Both aromatic and non-aromatic ring structures are included in this category.
| Descriptor ID |
D006574
|
| MeSH Number(s) |
D03.633.100
|
| Concept/Terms |
Heterocyclic Compounds, 2-Ring- Heterocyclic Compounds, 2-Ring
- 2-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 2 Ring
- Two Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Two-Ring
- Fused Heterocyclic Compounds, Two Ring
|
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 2-Ring".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 2-Ring".
This graph shows the total number of publications written about "Heterocyclic Compounds, 2-Ring" by people in this website by year, and whether "Heterocyclic Compounds, 2-Ring" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 | | 2020 | 1 | 1 | 2 | | 2023 | 2 | 0 | 2 | | 2024 | 3 | 1 | 4 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Heterocyclic Compounds, 2-Ring" by people in Profiles.
-
Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Gates D, Ezekowitz JA, Hernandez AF, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Armstrong PW. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet. 2025 Sep 27; 406(10510):1351-1362.
-
Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Felker GM, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, She L, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2025 Sep 27; 406(10510):1341-1350.
-
Saldarriaga CI, Zannad F, McMullan CJ, Xing A, Gates D, Anstrom KJ, Bonaca MP, Corda S, Ezekowitz JA, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor C, Patel M, Ponikowski P, Reddy YNV, Rosano GMC, Senni M, Udelson J, Voors AA, Butler J. Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial. Eur J Heart Fail. 2025 Aug; 27(8):1426-1435.
-
Reddy YNV, Butler J, Anstrom KJ, Blaustein RO, Bonaca MP, Corda S, Ezekowitz JA, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor C, Patel M, Ponikowski P, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F. Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial. Eur J Heart Fail. 2025 Feb; 27(2):209-218.
-
Santoro N. Neurokinin receptor antagonists as potential nonhormone treatments for vasomotor symptoms. Menopause. 2024 Oct 01; 31(10):923-925.
-
Neal-Perry G, Santoro N, Cano A, Nappi RE, Shapiro M, Ottery FD. Totality of evidence refutes neoplasm risk with fezolinetant. Lancet. 2024 05 18; 403(10440):1987-1988.
-
Santoro N, Nappi RE, Neal-Perry G, English M, King DD, Yamaguchi Y, Ottery FD. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2). Menopause. 2024 Apr 01; 31(4):247-257.
-
Wright AC, Beaudoin FL, McQueen RB, Yeung K, Moradi A, Herron-Smith S, Gutierrez E, Lin GA, Pearson SD. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council. J Manag Care Spec Pharm. 2023 06; 29(6):692-698.
-
Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. Obstet Gynecol. 2023 04 01; 141(4):737-747.
-
Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020 12; 27(12):1350-1356.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|